Head-to-head evidence
Paliperidone palmitate (Invega Hafyera) vs Ziprasidone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Paliperidone palmitate (Invega Hafyera)
Marketed by Johnson & Johnson
NCT03345342 · Phase 3 · completed
After an open-label stabilization phase, 702 participants were randomized to six-month or three-month paliperidone palmitate and treated double-blind with matching injections, including placebo injections to preserve masking. The primary endpoint was the clinical outcome of time to relapse, but the registry reports that the median was not estimable in either group and does not provide a p-value or confidence interval, so the result cannot be classified as clearly met or missed.
Ziprasidone
Marketed by Pfizer and partners
NCT00159770 · Phase 3 · completed
The study used randomization and active comparators but was open-label, with 290 participants, and its primary clinical endpoint was PANSS symptom change. No results are posted, so the primary endpoint cannot be classified as met or missed.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Paliperidone palmitate (Invega Hafyera)'s landscape · Ziprasidone's landscape